Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

October 31, 2009

Conditions
Early Parkinson Disease
Interventions
DRUG

aplindore MR tablets or Placebo

aplindore MR tablets administered BID for about 13 weeks

Trial Locations (25)

12208

Albany Medical College (037), Albany

14618

University of Rochester (001), Rochester

19107

University of Pennsylvania (018), Philadelphia

27705

Duke University Medical Center (119), Durham

33136

University of Miami (014), Miami

33486

Parkinson's Disease & Movement Disorders Center of Boca Raton (196), Boca Raton

33606

University of South Florida (019), Tampa

35294

University of Alabama At Birmingham (052), Birmingham

40205

University of Louisville (087), Louisville

40536

University of Kentucky (172), Lexington

45219

University of Cincinnati/Cincinnati Children's Hospital (089), Cincinnati

53226

Medical College of Wisconsin (104), Milwaukee

62794

Southern Illinois University (138), Springfield

63110

Washington University (027), St Louis

70121

Ochsner Clinic Foundation (207), New Orleans

71103

LSU Health Science Center Shreveport (132), Shreveport

77030

Baylor College of Medicine (007), Houston

80113

Colorado Neurological Institute (052), Englewood

85259

Mayo Clinic Arizona (060), Scottsdale

94085

The Parkinson's Institute (012), Sunnyvale

98034

Booth Gardner Parkinson's Care Center (220), Kirkland

06810

Associated Neurologists, PC (190), Danbury

06040

Eastern Connecticut Neurology Specialists (215), Manchester

06510

Institute for Neurodegenerative Disorders (034), New Haven

02118

Boston University (040), Boston

Sponsors
All Listed Sponsors
lead

Neurogen Corporation

INDUSTRY